FOLH1 and posterior cortical atrophy: The randomized, recruiting, phase I/II Nautilius is a single-center (US) trial evaluating 2 cycles of [177Lu]Lu-rhPSMA-10.1 with and without Degarelix (ADT) in 36 high-risk, localized and locoregional (M1 on PSMA PET are allowed) PSMA PET-positive (prostatic SUVmax > 8) PCa, candidate for RPE.